Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF)

NCT04939441 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Chronic Hepatitis B

Interventions

DRUG: Tenofovir alafenamide

Sponsor

Jidong Jia

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]